Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma

Netherlands Journal of Medicine

Volumn 57, Issue 4, 2000, Pages 150-156

  Lips, P ^a   Comans, E F I ^a   Hoekstra, O S ^a   Van Der Poest Clement, E ^a   Van Mourik, J C ^a   Teule, G J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Differentiated thyroid carcinoma; Iodine 131 uptake; Metastases of thyroid carcinoma; Positron emission tomography; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MEDICAL DECISION MAKING; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SCINTIGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADULT; AFTERCARE; AGED; CARCINOMA, PAPILLARY; CASE REPORT; FEMALE; FLUDEOXYGLUCOSE F 18; HUMAN; IODINE RADIOISOTOPES; MALE; MIDDLE AGE; PATIENT SELECTION; PRACTICE GUIDELINES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033834592     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(00)00067-X     Document Type: Article

References (16)

1. Aim K.B. Papillary thyroid carcinoma: etiology, assessment and therapy. Endocrinol Metab Clin NA. 24:1995;711-760.
2. Grebe S.K.G., Hay I.D. Follicular thyroid cancer. Endocrinol Metab Clin NA. 24:1995;761-802.
3. Schlumberger M.J. Papillary and follicular thyroid carcinoma. New Engl J Med. 338:1998;297-306.
4. Sweeney D.C., Johnston G.S. Radio-iodine therapy for thyroid cancer. Endocrinol Metab Clin NA. 24:1995;803-840.
5. Spencer C.A., Wang C.C. Thyroglobulin measurement: techniques, clinical benefits and pitfalls. Endocrinol Metab Clin NA. 24:1995;841-864.
6. Strauss L.G., Conti P.S. The application of PET in clinical oncology. J Nucl Med. 32:1991;623-648.
7. 131iodine uptake in thyroid cancer. J Nucl Med. 37:1996;1468-1472.
8. 131iodine whole body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 24:1997;1342-1348.
9. Fridrich L., Messa C., Landoni C., Lucignani G., Moncayo R., Kendler D., et al. Whole body scintigraphy with 99Tc-MIBI, 18-FDG and 131-I in patients with metastatic thyroid carcinoma. Nucl Med Commun. 18:1997;3-9.
10. Grunwald F., Menzel C., Bender H., Palmedo H., Willkomm P., Ruhlmann J., Franckson T., Biersack H.J. Comparison of [18]FDG-PET with (131)iodine and Tc-99m-Sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 7:1997;327-335.
11. Tinteren van H., Hoekstra O.S., Smit E.F., et al. Randomized clinical trial to evaluate the cost-effectiveness of PET added to conventional diagnosis in NSCLC. Proc. Am Soc Clin Oncol. 19:2000;482. (abstract).
12. Comans E.F.I., Hoekstra O.S., Hoekman K., et al. Meerwaarde van PET met de tracer 18F-fluorodeoxyglucose bij klinische probleemgevallen in de oncologie. Ned Tijdschr Geneesk. 144:2000;1520-1528.
13. Hooft L., Hoekstra O.S., Deville W., et al. Diagnostic accuracy of 18 FDG-PET in papillary or follicular thyroid cancer: a systematic review. Proceeding 16th ISTAHC :2000;45. (abstract).
14. Brandt-Mainz K., Muller S.P., Sonnenschein W., Bockisch A. Technetium-99m-furifosmin in the follow-up of differentiated thyroid carcinoma. J Nucl Med. 39:1998;1536-1541.
15. Chung J.K., So Y., Lee J.S., Choi C.W., Lim S.M., Lee D.S., Hong S.W., Young Lee M.C., Cho B.Y. Value of FDG-PET in papillary thyroid carcinoma with negative 131-I whole-body scan. J Nucl Med. 40:1999;986-992.
16. Alnafisi N.S., Driedger A.A., Coates G., Moote D.J., Raphael S.J. FDG-PET of recurrent or metastatic 131-I-negative papillary thyroid carcinoma. J Nucl Med. 41:2000;1010-1015.